Cited by 114Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

BRI2 Interacts with Amyloid Precursor Protein (APP) and Regulates Amyloid β (Aβ) Production

Open access
Fotinopoulou, Angeliki, Tsachaki, Maria, Vlavaki, Maria, Poulopoulos, Alexandros, Rostagno, Agueda, Frangione, Blas, Ghiso, Jorge, Efthimiopoulos, Spiros·2005·Journal of Biological Chemistry

Abstract

Transmembrane proteins BRI2 and amyloid precursor protein (APP) co-localize with amyloid beta (Abeta) lesions in sporadic Alzheimer disease and mutations in both precursor proteins are linked to early-onset familial cases of cerebral amyloidosis associated with dementia and/or cerebral hemorrhage. A specific interaction between BRI2 and APP was unveiled by immunoprecipitation experiments using transfected and non-transfected cells. The use of deletion mutants further revealed that stretches 648-719 of APP751 and 46-106 of BRI2, both inclusive of the full transmembrane domains, are sufficient for the interaction. Removal of most of the APP and BRI2 extracellular domains without affecting the interaction implies that both proteins interact when are expressed on the same cell membrane (cis) rather than on adjacent cells (trans). The presence of BRI2 had a modulatory effect on APP processing, specifically increasing the levels of cellular APP as well as beta-secretase-generated COOH-terminal fragments while decreasing the levels of alpha-secretase-generated COOH-terminal fragments as well as the secretion of total APP and Abeta peptides. Determining the precise molecular pathways affected by the specific binding between APP and BRI2 could result in the identification of common therapeutic targets for these sporadic and familial neurodegenerative disorders.

Integrity signals

Registry

Crossref · 10.1074/jbc.c500231200

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Previous studies demonstrated a potential interaction between BRI2 and APP.

    “Previous studies had demonstrated a potential interaction between BRI2 and APP and noted that BRI2 overexpression increased APP C-terminal fragment ␤ (CTF␤) and reduced A␤ secretion in cultured cells (Fotinopoulou et al., 2005;Matsuda et al., 2005).”

    From BRI2 (ITM2b) Inhibits A  Deposition In Vivo (2008) · cites this paper as Fotinopoulou et al., 2005

  • BRI2 overexpression increased APP C-terminal fragment β (CTFβ) and reduced Aβ secretion in cultured cells.

    “Previous studies had demonstrated a potential interaction between BRI2 and APP and noted that BRI2 overexpression increased APP C-terminal fragment ␤ (CTF␤) and reduced A␤ secretion in cultured cells (Fotinopoulou et al., 2005;Matsuda et al., 2005).”

    From BRI2 (ITM2b) Inhibits A  Deposition In Vivo (2008) · cites this paper as Fotinopoulou et al., 2005

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Fotinopoulou, A., Tsachaki, M., Vlavaki, M., Poulopoulos, A., Rostagno, A., Frangione, B., Ghiso, J., & Efthimiopoulos, S.
Affiliations
National and Kapodistrian University of Athens (GR)
Corresponding author
Efthimiopoulos, Spiros
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2005-09
Volume
280
Issue
35
Pages
30768-30772
ISSN
0021-9258 (ISSN-L)
OpenAlex
W2050673616
Cited by
114
References
28
Citations by year
2026: 1 · 2025: 3 · 2024: 5 · 2023: 4 · 2022: 5 · 2021: 4 · 2020: 9 · 2019: 2 · 2018: 6 · 2017: 4 · 2016: 8 · 2015: 5 · 2014: 9 · 2013: 7 · 2012: 5
FWCI
2.98
Type
journal article
Language
en
Open access
Locations
  • Journal of Biological Chemistry (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Institute on Aging (P01AG010491, AG10491, R01AG008721, AG-08721, AG05891)
  • National Institute of Neurological Disorders and Stroke (NS 38777, R01NS038777)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
BRI2, amyloid precursor protein, amyloid-beta production, APP processing, APP751, beta-secretase, alpha-secretase, protein-protein interaction, Alzheimer's disease, cerebral amyloidosis, transmembrane domain, cis-interactions, therapeutic target
MeSH terms
Amyloid, Cell Line, Humans, Membrane Glycoproteins, Membrane Proteins, Mutation, Peptide Fragments, Protein Binding, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Neurodegenerative Diseases, Protein Isoforms, Adaptor Proteins, Signal Transducing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review